Pooya Hemami
Pooya Hemami is a licensed optometrist with more than eight years of experience in life sciences equity research. Prior to joining Edison Investment Research, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and a master's degree in business administration (finance concentration) from McGill University. He received his CFA charter in 2011.
Recent Quotes
"BCLI is planning a Phase 2 NurOwn study in Israel, to start by 2015E."
—
Pooya Hemami, Edison Investment Research
(9/23/15)
more >
"If CANF's product can show decent efficacy, while maintaining the reasonable safety profile shown thus far, it is positioned to do well."
—
The Life Sciences Report Interview with Pooya Hemami
(10/15/14)
more >
"Our risk-adjusted NPV for BLU continues to reflect upside."
—
Pooya Hemami, Edison Investment Research
(10/6/14)
more >
"BLU's investment case includes premium pricing potential for Kiacta."
—
Pooya Hemami, Edison Investment Research
(6/30/14)
more >
"BLU is fully funded beyond the Kiacta study results."
—
Pooya Hemami, Edison Investment Research
(5/12/14)
more >
"BLU's reduction in the time to Kiacta phase 3 study data is positive."
—
Pooya Hemami, Edison Investment Research
(1/7/14)
more >
"BLU divested its noncore assets to focus on Kiacta and Shigamabs."
—
Pooya Hemami, Edison Investment Research
(11/8/13)
more >
"Following the Zenith spinout, RVX retains rights to lead candidate RVX-208."
—
Pooya Hemami, Edison Investment Research
(6/14/13)
more >
